Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

BackgroundFarnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that there are several other potential targets for this drug class. The FTI tipifarnib (ZARNESTRA™, R115777) has recently demonstrated clinical responses in adults with refractory and relapsed acute leukemias. This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML).MethodsTipifarnib-mediated gene expression changes in 3 AML cell lines and bone marrow samples from two patients with AML were analyzed on a cDNA microarray containing approximately 7000 human genes. Pathways associated with these expression changes were identified using the Ingenuity Pathway Analysis tool.ResultsThe expression analysis identified a common set of genes that were regulated by tipifarnib in three leukemic cell lines and in leukemic blast cells isolated from two patients who had been treated with tipifarnib. Association of modulated genes with biological functional groups identified several pathways affected by tipifarnib including cell signaling, cytoskeletal organization, immunity, and apoptosis. Gene expression changes were verified in a subset of genes using real time RT-PCR. Additionally, regulation of apoptotic genes was found to correlate with increased Annexin V staining in the THP-1 cell line but not in the HL-60 cell line.ConclusionsThe genetic networks derived from these studies illuminate some of the biological pathways affected by FTI treatment while providing a proof of principle for identifying candidate genes that might be used as surrogate biomarkers of drug activity.

[1]  D. Coppola,et al.  The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[2]  M. Jackson,et al.  Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[4]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[5]  M. Morgan,et al.  Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. , 2001, Blood.

[6]  G. Prendergast,et al.  Non-Ras targets of farnesyltransferase inhibitors: focus on Rho , 1998, Oncogene.

[7]  A. Adjei,et al.  Farnesyl transferase inhibitors as anticancer agents. , 2002, European journal of cancer.

[8]  G. Ahmann,et al.  Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma , 2003, Blood.

[9]  E. Estey,et al.  Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Lancet,et al.  Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis , 2003, Leukemia.

[11]  S. Sebti,et al.  Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ , 2000, Oncogene.

[12]  R. Kurzrock,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and , 2022 .

[13]  Channing J Der,et al.  Farnesyltransferase inhibitors: promises and realities. , 2002, Current opinion in pharmacology.

[14]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[15]  R. Kurzrock,et al.  Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. , 2002, Seminars in hematology.

[16]  C. Erlichman,et al.  Comparison of potential markers of farnesyltransferase inhibition. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[18]  G. Prendergast,et al.  Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. , 2002, Cancer research.

[19]  J. Karp,et al.  Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. , 2003, Blood.

[20]  R. Bataille,et al.  Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells , 2002, Leukemia.

[21]  G. Prendergast,et al.  Genetic Response to Farnesyltransferase Inhibitors: Proapoptotic Targets of RhoB , 2003, Cancer biology & therapy.